ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company
that is developing immune based therapies for the treatment of various
forms of cancer, announced today it received a Notice of Allowance from
the United States Patent and Trademark Office covering technology
relating to monoclonal antibodies that bind to certain epitopes present
on pancreatic cancers. This patent will broaden the Company’s
proprietary intellectual property for ICT-109 and ICT-37, two of the
Company’s monoclonal antibody product candidates.
“The notice of allowance further strengthens
ImmunoCellular’s intellectual property portfolio.”
ICT-109 and ICT-37 are humanized monoclonal antibodies that target small
cell lung cancer and pancreatic cancer. ICT-109 antibody specifically
binds to certain glycosylations (sugar structures) present on CEA-CAM6
and CEA-CAM5, which are highly expressed on malignant cells, while
ICT-37 specifically targets CEA-CAM5.
“This is a very good news for us,” commented Dr. Manish Singh, PhD.,
President and CEO of IMUC. “The notice of allowance further strengthens
ImmunoCellular’s intellectual property portfolio.” The Company also has
7 granted US patents and 8 issued international patents and over 25
pending patents.
In preclinical in-vitro testing, ICT-109 has been demonstrated to bind
to 100% of pancreatic cancer tissues and has demonstrated an ability to
detect the antigen in the blood sample of the patients. By combining
ICT-109 with additional biomarkers, it may be possible to detect
pancreatic cancer and lung cancers during their early stage, which
usually results in longer survival times for those patients.
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis